Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab with Chemotherapy in HIV-infected NSCLC Patients
NCT04499053Phase 2Recruiting
- Sponsor
- Georgetown University
- Start
- Dec 2020
- Primary completion
- Feb 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in non-small cell lung cancer (NSCLC), sponsored by Georgetown University. Started Dec 2020; status: recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04499053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04499053.